Ioannis Dikaios, Harald Althaus, Eduardo Angles-Cano, Uta Ceglarek, Stefan Coassin, Christa M Cobbaert, Vincent Delatour, Benjamin Dieplinger, Matthias Grimmler, Andrew N Hoofnagle, Gerhard M Kostner, Florian Kronenberg, Zsusanna Kuklenyik, Alicia N Lyle, Urban Prinzing, L Renee Ruhaak, Hubert Scharnagl, Hubert W Vesper, Liesbet Deprez
BACKGROUND: Elevated concentrations of lipoprotein(a) [Lp(a)] are directly related to an increased risk of cardiovascular diseases, making it a relevant biomarker for clinical risk assessment. However, the lack of global standardization of current Lp(a) measurement procedures (MPs) leads to inconsistent patient care. The International Federation for Clinical Chemistry and Laboratory Medicine working group on quantitating apolipoproteins by mass spectrometry (MS) aims to develop a next-generation SI (International system of units)-traceable reference measurement system consisting of a MS-based, peptide-calibrated reference measurement procedure (RMP) and secondary serum-based reference materials (RMs) certified for their apolipoprotein(a) [apo(a)] content...
March 1, 2023: Clinical Chemistry